Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS)
Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier
Medical Hypotheses (2020) Vol. 143, pp. 110112-110112
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
Flavio Cadegiani, John McCoy, Carlos Gustavo Wambier, et al.
Cureus (2021)
Open Access | Times Cited: 66
SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism
Nitin Kumar, Yu Zuo, Srilakshmi Yalavarthi, et al.
Viruses (2021) Vol. 13, Iss. 11, pp. 2209-2209
Open Access | Times Cited: 49
Races of small molecule clinical trials for the treatment of COVID‐19: An up‐to‐date comprehensive review
Suwen Hu, Songwei Jiang, Qi Xiang, et al.
Drug Development Research (2021) Vol. 83, Iss. 1, pp. 16-54
Open Access | Times Cited: 46
COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection
Katarzyna Kotfis, Kacper Lechowicz, Sylwester Drożdżal, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 1, pp. 71-71
Open Access | Times Cited: 38
Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment
Zemene Demelash Kifle, Akeberegn Gorems Ayele, Engidaw Fentahun Enyew
Journal of Environmental and Public Health (2021) Vol. 2021, pp. 1-11
Open Access | Times Cited: 33
Angiotensin-Converting Enzyme 2 Expression and Severity of SARS-CoV-2 Infection
Sarah Alabsi, Atharva Dhole, Sameh Hozayen, et al.
Microorganisms (2023) Vol. 11, Iss. 3, pp. 612-612
Open Access | Times Cited: 12
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients
Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier, et al.
New Microbes and New Infections (2021) Vol. 43, pp. 100915-100915
Open Access | Times Cited: 27
COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery
Sunny Kumar, Malini Basu, Pratyasha Ghosh, et al.
Genes & Diseases (2023) Vol. 10, Iss. 4, pp. 1402-1428
Open Access | Times Cited: 11
Expression Level Analysis of ACE2 Receptor Gene in African-American and Non-African-American COVID-19 Patients
Marion N. Nyamari, Kauthar M. Omar, Ayorinde F. Fayehun, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 10
Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein
Eva Jover, Lara Matilla, Mattie Garaikoetxea, et al.
Biomedicines (2021) Vol. 9, Iss. 6, pp. 639-639
Open Access | Times Cited: 26
Is Spironolactone the Preferred Renin–Angiotensin–Aldosterone Inhibitor for Protection Against COVID-19?
Christopher S. Wilcox, Bertram Pitt
Journal of Cardiovascular Pharmacology (2020) Vol. 77, Iss. 3, pp. 323-331
Open Access | Times Cited: 25
Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic
Hongyin Chen, Jiangyun Peng, Tengyao Wang, et al.
Biochemical Pharmacology (2022) Vol. 208, pp. 115370-115370
Open Access | Times Cited: 14
Exploration of multifaceted molecular mechanism of angiotensin-converting enzyme 2 (ACE2) in pathogenesis of various diseases
Aditi D. Kunvariya, Shivani A. Dave, Zeal J. Modi, et al.
Heliyon (2023) Vol. 9, Iss. 5, pp. e15644-e15644
Open Access | Times Cited: 8
An Overview of Sex Hormones in Relation to SARS-CoV-2 Infection
Marzieh Saei Ghare Naz, Mojdeh Banaei, Sareh Dashti, et al.
Future Virology (2021) Vol. 16, Iss. 8, pp. 555-564
Open Access | Times Cited: 19
The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
Marco Vicenzi, Massimiliano Ruscica, Simona Iodice, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 9, pp. 2943-2943
Open Access | Times Cited: 19
Crosstalk between estrogen, dendritic cells, and SARS‐CoV‐2 infection
Daniela Mateus, Ana Isabel Sebastião, Mylène A. Carrascal, et al.
Reviews in Medical Virology (2021) Vol. 32, Iss. 3
Open Access | Times Cited: 16
The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort
Flavio Cadegiani, Ricardo Ariel Zimerman, Bruno Campello de Souza, et al.
Cureus (2021)
Open Access | Times Cited: 14
DrugRep-HeSiaGraph: when heterogenous siamese neural network meets knowledge graphs for drug repurposing
Zahra Ghorbanali, Fatemeh Zare‐Mirakabad, Najmeh Salehi, et al.
BMC Bioinformatics (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients.
Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier, et al.
Research Square (Research Square) (2020)
Open Access | Times Cited: 14
Effect of Spironolactone on COVID-19 in Patients With Underlying Liver Cirrhosis: A Nationwide Case-Control Study in South Korea
Dongsub Jeon, Minkook Son, Jonggi Choi
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 13
The Effects of Different Classes of Antihypertensive Drugs on Patients with COVID-19 and Hypertension: A Mini-Review
Farnoosh Nozari, Nasrin Hamidizadeh
International Journal of Hypertension (2022) Vol. 2022, pp. 1-8
Open Access | Times Cited: 9
Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients
Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 13
COVID‐19, androgens, and androgenic alopecia
Carlos Gustavo Wambier, Nina Mehta, Andy Goren, et al.
Dermatological Reviews (2020) Vol. 2, Iss. 3, pp. 146-153
Closed Access | Times Cited: 13
Cardiovascular Disease and COVID-19: Insight From Cases With Heart Failure
Yi Yang, Yanan Xu, Haibing Jiang, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 9
An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top